These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3811541)

  • 21. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1.
    Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM
    Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA polymorphisms as potential genetic risk markers for cardiovascular diseases.
    Cocozza S; Monticelli A; Garofalo S; Riccardi G; Cortese R; Quirico N; Ricci A; Cicerone R; Rossi F; Varrone S
    Boll Soc Ital Biol Sper; 1987 Sep; 63(9):771-7. PubMed ID: 2896009
    [No Abstract]   [Full Text] [Related]  

  • 23. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis.
    Tybjaerg-Hansen A; Nordestgaard BG; Gerdes LU; Faergeman O; Humphries SE
    Atherosclerosis; 1993 May; 100(2):157-69. PubMed ID: 8102848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA polymorphic sites in the human ApoAI-CIII-AIV cluster: Taq I and Ava I.
    Cohen T; Karathanasis SK; Kazazian HH; Antonarakis SE
    Nucleic Acids Res; 1986 Feb; 14(4):1924. PubMed ID: 3005989
    [No Abstract]   [Full Text] [Related]  

  • 25. SstI RFLP and hypertension as risk factors for extracoronary atherosclerosis in a male population of southern Italy.
    Pujia A; Gnasso A; Siclari D; Dominijanni A; Zingone A; Marasco O; Mele E; Cortese C; Colonna A; Mattioli PL
    Artery; 1994; 21(4):208-21. PubMed ID: 8830647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis.
    Vergnes L; Baroukh N; Ostos MA; Castro G; Duverger N; Nanjee MN; Najib J; Fruchart JC; Miller NE; Zakin MM; Ochoa A
    Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2267-74. PubMed ID: 11031214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three new polymorphisms of the ApoAI-CIII-AIV gene cluster.
    Xu CF; Talmud P; Humphries S
    Mol Cell Probes; 1994 Aug; 8(4):331-2. PubMed ID: 7870077
    [No Abstract]   [Full Text] [Related]  

  • 28. [Genetic aspects of atherogenic dyslipoproteinemias].
    de Gennes JL
    Ann Biol Clin (Paris); 1986; 44(5):556-8. PubMed ID: 3813140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The relationship of apoB gene polymorphism to dyslipoproteinemia as the cause of atherosclerosis].
    Kravchenko NA
    Tsitol Genet; 1995; 29(4):84-7. PubMed ID: 8604528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis.
    Hegele RA
    Clin Biochem; 1997 Apr; 30(3):183-8. PubMed ID: 9167893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA restriction polymorphisms of the apolipoprotein AI-CIII-AIV gene cluster: a genetic determinant of atherosclerosis in type 2 (non-insulin-dependent) diabetes mellitus.
    Renard E; Dupuy AM; Monnier L; Crastes de Paulet A
    Diabet Med; 1991 May; 8(4):354-60. PubMed ID: 1677323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical disorders of lipoprotein metabolism.
    Brewer HB; Gregg RE; Hoeg JM; Law S
    Monogr Atheroscler; 1986; 14():159-68. PubMed ID: 3736557
    [No Abstract]   [Full Text] [Related]  

  • 33. [Interaction between genes and diet as a determinant of the plasma levels of cholesterol].
    López Miranda J; Ordovás JM; Pérez Jiménez F
    Med Clin (Barc); 1998 Oct; 111(14):546-51. PubMed ID: 9859082
    [No Abstract]   [Full Text] [Related]  

  • 34. [Familial dyslipoproteinemia].
    Maeda H; Uzawa H
    Rinsho Byori; 1983 Feb; 31(2):117-20. PubMed ID: 6343674
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of genetic mechanisms on plasma lipoprotein metabolism and the pathogenesis of atherosclerosis.
    Kwiterovich PO; Bachorik PS; Chatterjee S
    Prog Clin Biol Res; 1979; 32():65-112. PubMed ID: 230521
    [No Abstract]   [Full Text] [Related]  

  • 36. [Apolipoprotein A-I and high-density lipoprotein cholesterol in familial hyperlipoproteinemias].
    Raslová K; Oravec S; Kolesár P; Lukácová M
    Vnitr Lek; 1986 Jun; 32(6):549-55. PubMed ID: 3090780
    [No Abstract]   [Full Text] [Related]  

  • 37. Genetics and molecular biology.
    Chamberlain JC
    Curr Opin Lipidol; 1997 Oct; 8(5):U63-4. PubMed ID: 9335960
    [No Abstract]   [Full Text] [Related]  

  • 38. [Characteristics of apolipoprotein polymorphism in a Hungarian population].
    Császár A
    Orv Hetil; 1997 Sep; 138(36 Suppl 2):2296-7. PubMed ID: 9340574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Genetic metabolic defects in adults].
    Schwandt P; Richter WO
    Internist (Berl); 1989 Sep; 30(9):547-55. PubMed ID: 2681039
    [No Abstract]   [Full Text] [Related]  

  • 40. [Genes, dyslipoproteinemias and atherosclerosis: from the experimental to the therapeutic].
    Fruchart JC; Duriez P
    Ann Endocrinol (Paris); 1999 Sep; 60(3):175-6. PubMed ID: 10520406
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.